New Meta-Analysis Shows Treos Bio’s Promiscuous Epitopes in Their Off-The-Shelf Colorectal Cancer Immunotherapy Produce Stronger Immune Response than Traditional Epitopes
September 09 2024 - 4:16PM
Treos Bio announced the results of a meta-analysis from three
clinical trials evaluating its investigational off-the-shelf
immunotherapy, PolyPEPI1018, for the treatment of microsatellite
stable metastatic colorectal cancer (MSS mCRC). The analysis
revealed that prioritized peptides, selected using Treos'
proprietary computational technology, were key in driving immune
responses and clinical outcomes across the studies.
The results will be presented in a poster session at the 2024
European Society of Medical Oncology (ESMO) annual meeting in
Barcelona on September 15. The poster, titled "149P -
Evaluation of HLA Genotype as a Predictive Biomarker for
Immunological and Clinical Responses to PolyPEPI1018 Cancer Vaccine
in Colorectal Cancer," will detail these findings.
“Having completed three successful studies of our precision
cancer vaccine in MSS mCRC, we recognize the urgent need for better
treatment options for these patients,” said Dr. Christopher
Gallen, CEO of Treos Bio. “This includes identifying likely
responders to these therapies.”
PolyPEPI1018 is an off-the-shelf, multi-peptide vaccine for
colorectal cancer that has consistently demonstrated the ability to
induce robust immunological responses associated with clinical
benefits. These effects were observed in both first-line
maintenance MSS mCRC (OBERTO-101) and in late-stage MSS mCRC, in
combination with standard-of-care treatments (OBERTO-201) and a
PD-(L)1 inhibitor (OBERTO-301).
The meta-analysis confirmed that HLA genotype plays a
crucial role in predicting immunological and clinical responses to
the PolyPEPI1018 vaccine. Treos Bio’s personalized epitopes,
or "PEPIs," which bind to at least three HLA alleles, were shown to
be more effective at activating T cells and predicting immune
responses than traditional epitopes, which bind to fewer HLA
alleles.
The number of predicted PEPIs correlated with both tumor
shrinkage and overall survival in vaccinated subjects, highlighting
the importance of considering HLA genotype when predicting
treatment outcomes with PolyPEPI1018.
“Data from this meta-analysis highlights the consistency of the
immune-activity relationship observed in these studies and further
increases our confidence in the results obtained from these
single-arm trials,” said Dr. Joleen Hubbard, Principal
Investigator of the studies.
Dr. Eniko R. Toke, Chief Scientific Officer for Treos
Bio, added that the findings align with previous observations
made by Treos and other research groups, demonstrating that immune
responses to multiple vaccine peptides correlate with clinical
outcomes.
“For the first time, our data shows how these multi-peptide
immune responses are connected to patients' HLA genetics, the
key driver behind patient heterogeneity and varying responses to
cancer immunotherapies,” she said.
About Treos Bio Limited
Treos Bio, headquartered in London, is a clinical stage company
introducing a disruptive computational technology to
change the paradigm of cancer immunotherapy development by
resolving the dual challenges of patient and tumor heterogeneity.
We use proprietary therapeutic peptides, produced through
commercially scalable processes without need for tumor biopsy, to
stimulate clinically effective cancer-specific immune responses in
patients predicted by our diagnostic tests to respond. Treos is
currently advancing clinical development of its PolyPEPI
immunotherapy for metastatic colorectal cancer, while preclinical
development is in advanced stages for additional members of the
PolyPEPI family. These off-the-shelf therapies are designed for the
general population of patients with hepatocellular, ovarian,
gastric, breast, bladder, and lung cancers, as well as melanoma.
Treos' patient-focused immunotherapy design also facilitates the
development of rapidly formulated personalized immunotherapies for
individual patients.
For more information, visit www.treosbio.com
Media Contact:Daniel LevineLevine Media Group+1
(510) 280-5405danny@levinemediagroup.com